Your browser is no longer supported. Please, upgrade your browser.
Akouos, Inc.
Index- P/E- EPS (ttm)- Insider Own3.41% Shs Outstand34.38M Perf Week6.15%
Market Cap685.86M Forward P/E- EPS next Y-1.98 Insider Trans-45.05% Shs Float19.07M Perf Month28.27%
Income- PEG- EPS next Q-0.46 Inst Own93.90% Short Float11.07% Perf Quarter8.01%
Sales- P/S- EPS this Y-328.10% Inst Trans-0.48% Short Ratio14.52 Perf Half Y-8.86%
Book/sh20.95 P/B0.97 EPS next Y43.20% ROA- Target Price33.00 Perf Year-
Cash/sh9.51 P/C2.14 EPS next 5Y70.30% ROE- 52W Range15.38 - 30.67 Perf YTD2.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-33.58% Beta-
Dividend %- Quick Ratio37.40 Sales past 5Y- Gross Margin- 52W Low32.44% ATR1.60
Employees57 Current Ratio37.40 Sales Q/Q- Oper. Margin- RSI (14)62.46 Volatility14.34% 8.32%
OptionableNo Debt/Eq0.00 EPS Q/Q-369.20% Profit Margin- Rel Volume6.13 Prev Close19.95
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume145.41K Price20.37
Recom1.50 SMA2014.76% SMA5010.86% SMA2000.78% Volume825,404 Change2.11%
Jul-21-20Initiated Piper Sandler Overweight $40
Jul-21-20Initiated Cowen Outperform
Jul-21-20Initiated BTIG Research Buy $35
Jul-21-20Initiated BofA Securities Buy $24
Jan-11-21 07:00AM  
Dec-24-20 11:16PM  
Dec-12-20 03:38PM  
Nov-23-20 09:00AM  
Nov-12-20 07:00AM  
Oct-01-20 07:00AM  
Sep-26-20 09:01AM  
Sep-24-20 08:00AM  
Sep-08-20 08:00AM  
Aug-13-20 07:00AM  
Aug-05-20 08:00AM  
Aug-03-20 08:00AM  
Jul-10-20 05:13PM  
Jun-30-20 04:05PM  
Jun-25-20 07:42PM  
Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PARMAR KUSHDirectorDec 29Sale18.00470,0008,460,000982,453Dec 31 09:32 PM
5AM Ventures V, L.P.10% OwnerDec 29Sale18.00470,0008,460,000982,453Dec 31 09:31 PM